XML 41 R17.htm IDEA: XBRL DOCUMENT
v3.20.2

Note 10 - Share-based Compensation and Other Benefit Plans | 12 Months Ended
--- | ---
Jun. 30, 2020
Notes to Financial Statements |
Share-based Payment Arrangement [Text Block] | Note 10. Share-based Compensation and Other Benefit Plans: The cost of employee services received in exchange for the award of equity instruments is based on the fair value of the award at the date of grant. Compensation cost is recognized using a straight-line method over the vesting period and is net of estimated forfeitures. Stock option exercises and stock awards are satisfied through the issuance of new shares. Equity incentive plan: The Company's Second Amended and Restated 2010 Equity Incentive Plan (the Second A&R 2010 Plan) provides for the granting of incentive and nonqualified stock options, restricted stock, restricted stock units, performance shares, performance units and stock appreciation rights. There are 7.5 million shares of common stock authorized for grant under the Second A&R 2010 Plan. At June 30, 2020, there were 1.9 million shares of common stock available for grant under the Second A&R 2010 Plan. The maximum term of incentive options granted under the Second A&R 2010 Plan is ten years. The Second A&R 2010 Plan amended and restated the Company's Amended and Restate 2010 Equity Incentive Plan (the A&R 2010 Plan). The A&R 2010 Plan replaced the Company's 1998 Nonqualified Stock Option Plan (the 1998 Plan). The Second A&R 2010 Plan and the 1998 Plan (collectively, the Plans) are administered by the Board of Directors and its Executive Compensation Committee, which determine the persons who are to receive awards under the Plans, the number of shares subject to each award and the term and exercise price of each award. The number of shares of common stock subject to outstanding awards as of June 30, 2020 under the Second A&R 2010 Plan were 3.6 million. For June 30, 2019 under the Second A&R 2010 Plan and the 1998 Plan were 3.6 million and 20,000, respectively. On April 26, 2018 the Executive Compensation Committee of the Board of Directors approved a modification to the Plans. The modification implements a new retirement policy that permits retirees to continue vesting in certain time-based stock options granted during employment, resulting in accelerated stock compensation expense for those employees meeting the definition of retirement eligible. This modification resulted in an additional $8.3 million of expense during fiscal year 2018 and affected all employees who participate in the plan. The fair values of options granted under the Plans were estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions used:
|  | Year Ended June 30, |
|  | 2020 |  |  | 2019 |  |  | 2018 |
Dividend yield |  |  | 0.67% |  |  |  |  | 0.74% |  |  |  |  | 1.1% |  |
Expected volatility |  | 22% | - | 24% |  |  | 20% | - | 23% |  |  | 21% | - | 24% |
Risk-free interest rates |  | 1.3% | - | 1.9% |  |  | 2.5% | - | 3.0% |  |  | 1.7% | - | 2.8% |
Expected lives (years) |  |  | 4.0 |  |  |  |  | 4.1 |  |  |  |  | 4.7 |  |
The dividend yield is based on the Company's historical annual cash dividend divided by the market value of the Company's common stock. The expected annualized volatility is based on the Company's historical stock price over a period equivalent to the expected life of the option granted. The risk-free interest rate is based on U.S. Treasury constant maturity interest rates with a term consistent with the expected life of the options granted. Stock option activity under the Plans for the three years ended June 30, 2020, consists of the following (shares in thousands):
|  | Number of Shares (in thousands) |  |  | Weighted Average Exercise Price |  |  | Aggregate Intrinsic Value (millions) |  |  | Weighted Average Contractual Life (years) |
Outstanding at June 30, 2017 |  |  | 2,821 |  |  | $ | 98.42 |  |  |  |  |  |  |  |  |
Granted |  |  | 1,087 |  |  |  | 120.67 |  |  |  |  |  |  |  |  |
Forfeited |  |  | (252 | ) |  |  | 86.62 |  |  |  |  |  |  |  |  |
Exercised |  |  | (204 | ) |  |  | 111.51 |  |  |  |  |  |  |  |  |
Outstanding at June 30, 2018 |  |  | 3,452 |  |  | $ | 105.17 |  |  |  |  |  |  |  |  |
Granted |  |  | 917 |  |  |  | 173.89 |  |  |  |  |  |  |  |  |
Forfeited |  |  | (330 | ) |  |  | 129.93 |  |  |  |  |  |  |  |  |
Exercised |  |  | (383 | ) |  |  | 95.29 |  |  |  |  |  |  |  |  |
Outstanding at June 30, 2019 |  |  | 3,656 |  |  | $ | 121.16 |  |  |  |  |  |  |  |  |
Granted |  |  | 752 |  |  |  | 190.80 |  |  |  |  |  |  |  |  |
Forfeited |  |  | (56 | ) |  |  | 95.97 |  |  |  |  |  |  |  |  |
Exercised |  |  | (743 | ) |  |  | 157.45 |  |  |  |  |  |  |  |  |
Outstanding at June 30, 2020 |  |  | 3,609 |  |  | $ | 140.28 |  |  | $ | 446.7 |  |  |  | 4.3 |
Exercisable at June 30, 2018: |  |  | 1,151 |  |  |  | 90.75 |  |  |  |  |  |  |  |  |
Exercisable at June 30, 2019: |  |  | 1,467 |  |  |  | 98.70 |  |  |  |  |  |  |  |  |
Exercisable at June 30, 2020: |  |  | 1,564 |  |  |  | 112.60 |  |  | $ | 236.8 |  |  |  | 3.3 |
The weighted average fair value of options granted during fiscal 2020, 2019, and 2018 was $37.01, $34.66, and $22.07 respectively. The total intrinsic value of options exercised during fiscal 2020, 2019, and 2018 were $99.3 million, $159.0 million, and $10.6 million, respectively. The total fair value of options vested during fiscal 2020, 2019, and 2018 were $71.1 million, $31.7 million, and $8.8 million, respectively. Restricted common stock activity under the Plans for the three years ended June 30, 2020, consists of the following (units in thousands):
|  | Number of Shares (in thousands) |  |  | Weighted Average Grant Date Fair Value |  |  | Weighted Average Remaining Contractual Term (years) |
Unvested at June 30, 2017 |  |  | 32 |  |  | $ | 105.80 |  |  |  |  |
Granted |  |  | 20 |  |  |  | 125.05 |  |  |  |  |
Vested |  |  | (17 | ) |  |  | 104.66 |  |  |  |  |
Forfeited |  |  | - |  |  |  | - |  |  |  |  |
Unvested at June 30, 2018 |  |  | 35 |  |  | $ | 117.39 |  |  |  |  |
Granted |  |  | 15 |  |  |  | 177.93 |  |  |  |  |
Vested |  |  | (20 | ) |  |  | 116.76 |  |  |  |  |
Forfeited |  |  | - |  |  |  | - |  |  |  |  |
Unvested at June 30, 2019 |  |  | 30 |  |  | $ | 147.94 |  |  |  |  |
Granted |  |  | 15 |  |  |  | 193.48 |  |  |  |  |
Vested |  |  | (18 | ) |  |  | 142.12 |  |  |  |  |
Forfeited |  |  | - |  |  |  | - |  |  |  |  |
Unvested at June 30, 2020 |  |  | 28 |  |  | $ | 177.20 |  |  |  | 6.14 |
The total fair value of restricted shares that vested was $2.5 million for fiscal 2020, $2.3 million for fiscal 2019, and $1.7 million for fiscal 2018. Restricted stock unit activity under the Plans for the three years ended June 30, 2020, consists of the following (units in thousands):
|  | Number of Units (in thousands) |  |  | Weighted Average Grant Date Fair Value |  |  | Weighted Average Remaining Contractual Term (years) |
Outstanding at June 30, 2017 |  |  | 111 |  |  | $ | 106.39 |  |  |  |  |
Granted |  |  | 71 |  |  |  | 129.99 |  |  |  |  |
Vested |  |  | (16 | ) |  |  | 95.46 |  |  |  |  |
Forfeited |  |  | (18 | ) |  |  | 115.01 |  |  |  |  |
Outstanding at June 30, 2018 |  |  | 148 |  |  | $ | 117.95 |  |  |  |  |
Granted |  |  | 56 |  |  |  | 170.96 |  |  |  |  |
Vested |  |  | (28 | ) |  |  | 110.86 |  |  |  |  |
Forfeited |  |  | (36 | ) |  |  | 143.72 |  |  |  |  |
Outstanding at June 30, 2019 |  |  | 139 |  |  | $ | 134.17 |  |  |  |  |
Granted |  |  | 31 |  |  |  | 192.08 |  |  |  |  |
Vested |  |  | (51 | ) |  |  | 111.07 |  |  |  |  |
Forfeited |  |  | (3 | ) |  |  | 155.6 |  |  |  |  |
Outstanding at June 30, 2020 |  |  | 116 |  |  | $ | 159.25 |  |  |  | 5.20 |
The total fair value of restricted stock units that vested was $5.7 million for fiscal 2020, $3.1 million for fiscal 2019, and $1.6 million for fiscal 2018. The restricted stock units vest over a three-year period. Stock-based compensation cost of $32.4 million, $32.3 million, and $28.2 million was included in selling, general and administrative expense in fiscal 2020, 2019 and 2018, respectively. Additionally, Stock-based compensation costs of $1.6 million was included in cost of goods sold in 2020. As of June 30, 2020, there was $25.3 million of unrecognized compensation cost related to non-vested stock options, non-vested restricted stock units and non-vested restricted stock which will be expensed in fiscal 2021 through 2023 using a 3% forfeiture rate. The weighted average period over which the compensation cost is expected to be recognized is 1.9 years. Employee stock purchase plan: In fiscal year 2015, the Company established the Bio-Techne Corporation 2014 Employee Stock Purchase Plan (ESPP), which was approved by the Company's shareholders on October 30, 2014, and which is designed to comply with IRS provisions governing employee stock purchase plans. 200,000 shares were allocated to the ESPP. The Company recorded expense of $0.4 million, $0.5 million, and $0.3 million for the ESPP in fiscal 2020, 2019, and 2018, respectively. Profit sharing and savings plans: The Company has profit sharing and savings plans for its U.S. employees, which conform to IRS provisions for 401(k) plans. The Company makes matching contributions to the Plan. The Company has recorded an expense for contributions to the plans of $3.2 million, $2.8 million, and $2.5 million for the years ended June 30, 2020, 2019, and 2018, respectively. The Company operates defined contribution pension plans for its U.K. employees. The Company has recorded an expense for contributions to the plans of $1.4 million for each of the years ended June 30, 2020, 2019, and 2018. Performance incentive programs: In fiscal 2020, under certain employment agreements and a Management Incentive Plan available to executive officers and certain management personnel, the Company recorded cash bonuses of $10.5 million, granted options for 751,499 shares of common stock, issued 15,398 restricted common shares and 30,858 restricted stock units. In fiscal 2019 and fiscal 2018, the Company recorded cash bonuses of $9.3 million and $7.2 million, granted options for 618,898 and 553,750 shares of common stock, and issued 11,279 and 14,194 restricted common stock shares and 25,903 and 35,174 restricted stock, respectively.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration